Asia Pacific Genome Editing Market to Grow at a CAGR of 19.0% to reach US$ 3,557.63 million from 2021 to 2028

The genome editing market in Asia Pacific is expected to grow from US$ 1,051.58 million in 2021 to US$ 3,557.63 million by 2028; it is estimated to grow at a CAGR of 19.0% from 2021 to 2028.

Technological developments in healthcare IT allow the use of artificial intelligence (AI) for manufacturing CRISPR Systems. Developers working in the healthcare IT domain are engaged in analyzing the processes to control and monitor all the stages of product development. The focus is to develop technologies from discovering biomarkers to clinical trials and patient monitoring. A few companies have initiated implementing their expertise to use AI for digital manufacturing. Similarly, in June 2018, Celixir plc acquired Desktop Genetics to develop CRISPR-based gene editing. In August 2018, bluebird bio, Inc. and Gritstone Oncology, Inc. collaborated to develop and commercialize cell therapy products intended for cancer treatment. Under the agreement, Gritstone Oncology has utilized its proprietary EDGE artificial intelligence platform to analyze specific tumor types. EDGE AI platform has helped identify tumor-specific targets and natural T-cell receptors (TCRs) that are used as targets by bluebird bio to develop cell therapies. Further, Gritstone Oncology has utilized those identified targets to conduct development, manufacturing, and commercial processes. Thus, such innovations are expected to foster genome editing and enhance the market growth in the coming years.

In January 2020, after a series of cases of pneumonia in Wuhan, the Chinese health authorities, the capital city of Hubei province (China), announced that a novel coronavirus, officially known as severe acute respiratory syndrome coronavirus (SARS-CoV)-2, was responsible for these cases. COVID-19 has created an extraordinary emergency that is particularly affecting the supply chain. The supply chain disruptions, along with the enormous demand for effective therapies for the treatment of COVID 19 have put the healthcare research industry in a critical situation in the Asia Pacific region. However, many of the market players now realized the importance of gene therapy in the treatment of COVID 19 which is expected to raise demand for genome editing during the forecast period.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the Asia Pacific genome editing market. The Asia Pacific genome editing market is expected to grow at a good CAGR during the forecast period.

Asia Pacific Genome Editing Market Revenue and Forecast to 2028 (US$ Million)

Asia Pacific Genome Editing Market Segmentation

Asia Pacific Genome Editing Market – By Technology

• CRISPR
• TALEN
• Antisense
• Other

Asia Pacific Genome Editing Market – By Application

• Cell Line Engineering
• Genetic Engineering
• Diagnostic Applications
• Drug Discovery
• Others

Asia Pacific Genome Editing Market – By End User

• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes
• Clinical Research Organizations (CRO's)

Asia Pacific Genome Editing Market – By Country

• China
• Japan
• India
• South Korea
• Australia
• Rest of Asia Pacific

Asia Pacific Genome Editing Market – Companies Mentioned

• THERMO FISHER SCIENTIFIC INC.
• MERCK KGaA
• Lonza
• Horizon Discovery Group plc.            
• Integrated DNA Technologies         
• GenScript
• New England Biolabs
• Eurofins Scientific
• CRISPR Therapeutics

Asia Pacific Genome Editing Report Scope